



(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/7004 (2006.01)
A61K 9/16 (2006.01) A61P 3/04 (2006.01)
A61K 9/20 (2006.01) A61P 3/06 (2006.01)
A61K 31/431 (2006.01) A61P 3/10 (2006.01)

(21) International Application Number:

PCT/EP2010/051737

(22) International Filing Date:

11 February 2010 (11.02.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/152,317 13 February 2009 (13.02.2009) US
61/254,033 22 October 2009 (22.10.2009) US

(71) Applicant (for all designated States except US):
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EISENREICH, Wolfram** [DE/DE]; Boehringer Ingelheim GmbH, CD Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **LADYZHYNSKY, Nadia S.** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, ct 06877 (US). **LI, Daping** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, ct 06877 (US). **SCHULTZ, Leon** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, ct 06877 (US). **WANG,**

Zeren [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, ct 06877 (US). **MACHA, Sreeraj** [IN/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, ct 06877 (US). **BARTA, Albert** [DE/DE]; Boehringer Ingelheim GmbH, CD Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(74) Agent: **HAMMANN, Heinz**; c/o Boehringer Ingelheim GmbH, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING GLUCOPYRANOSYL DIPHENYLMETHANE DERIVATIVES, PHARMACEUTICAL DOSAGE FORM THEREOF, PROCESS FOR THEIR PREPARATION AND USES THEREOF FOR IMPROVED GLYCEMIC CONTROL IN A PATIENT




Fig. 3A

(57) Abstract: The present invention relates to pharmaceutical compositions comprising a SGLT-2 inhibitor, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.



— *as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*